Related references
Note: Only part of the references are listed.Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination
Sudarshini Ramanathan et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
S. Jarius et al.
JOURNAL OF NEUROINFLAMMATION (2018)
Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults The MOGADOR study
Alvaro Cobo-Calvo et al.
NEUROLOGY (2018)
Disease Course and Treatment Responses in Children With RelapsingMyelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Yael Hacohen et al.
JAMA NEUROLOGY (2018)
Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease
Shahd H. M. Hamid et al.
JAMA NEUROLOGY (2018)
Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders
Alexis Montcuquet et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders
Alexis Montcuquet et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
MOG antibody-related disorders: common features and uncommon presentations
Alvaro Cobo-Calvo et al.
JOURNAL OF NEUROLOGY (2017)
Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome
Eva-Maria Hennes et al.
NEUROLOGY (2017)
Clinical presentation and prognosis in MOG-antibody disease: a UK study
Maciej Jurynczyk et al.
BRAIN (2017)
Neuromyelitis optica and neuromyelitis optica spectrum disorders
Romain Marignier et al.
CURRENT OPINION IN NEUROLOGY (2017)
Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis
Maciej Jurynczyk et al.
BRAIN (2017)
Efficacy of rituximab in refractory neuromyelitis optica
N. Collongues et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Efficacy of rituximab in refractory neuromyelitis optica
N. Collongues et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome
Sven Jarius et al.
JOURNAL OF NEUROINFLAMMATION (2016)
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
Sven Jarius et al.
JOURNAL OF NEUROINFLAMMATION (2016)
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin
Sven Jarius et al.
JOURNAL OF NEUROINFLAMMATION (2016)
Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes
Maria Sepulveda et al.
JOURNAL OF NEUROLOGY (2016)
Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis
Peter C. Austin
STATISTICS IN MEDICINE (2016)
Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders A Systematic Review and Meta-analysis
Valentina Damato et al.
JAMA NEUROLOGY (2016)
Neuromyelitis optica spectrum disorders Comparison according to the phenotype and serostatus
Maria Sepulveda et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis
Melania Spadaro et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability
Helene Zephir et al.
JOURNAL OF NEUROLOGY (2015)
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk et al.
NEUROLOGY (2015)
Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease
Romana Hoeftberger et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS
Sung-Min Kim et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children
Yael Hacohen et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)
Corinna Trebst et al.
JOURNAL OF NEUROLOGY (2014)
Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab
Joanna Kitley et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)
Treatment of neuromyelitis optica: state-of-the-art and emerging therapies
Marios C. Papadopoulos et al.
NATURE REVIEWS NEUROLOGY (2014)
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
Douglas Kazutoshi Sato et al.
NEUROLOGY (2014)
Poor Responses to Interferon-Beta Treatment in Patients with Neuromyelitis Optica and Multiple Sclerosis with Long Spinal Cord Lesions
Kai-Chen Wang et al.
PLOS ONE (2014)
Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies A Comparative Study
Joanna Kitley et al.
JAMA NEUROLOGY (2014)
Mycophenolate Mofetil in the Treatment of Neuromyelitis Optica Spectrum Disorder
So-Young Huh et al.
JAMA NEUROLOGY (2014)
International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions
Lauren B. Krupp et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders
Simone Mader et al.
JOURNAL OF NEUROINFLAMMATION (2011)
Azathioprine Tolerability, efficacy, and predictors of benefit in neuromyelitis optica
C. Costanzi et al.
NEUROLOGY (2011)
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
H. L. Pellkofer et al.
NEUROLOGY (2011)
Interferon Beta Treatment in Neuromyelitis Optica Increase in Relapses and Aquaporin 4 Antibody Titers
Jacqueline Palace et al.
ARCHIVES OF NEUROLOGY (2010)
EFNS guidelines on diagnosis and management of neuromyelitis optica
J. Sellner et al.
EUROPEAN JOURNAL OF NEUROLOGY (2010)
Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
Peter C. Austin
STATISTICS IN MEDICINE (2009)
New natural history of interferon-β treated relapsing multiple sclerosis
Maria Trojano et al.
ANNALS OF NEUROLOGY (2007)